Former Chief Medical Officer · Immunovant, Inc. (IMVT)

Robert FAAAAI

FY2019 is the first fiscal year CompBrief holds for Robert FAAAAI as a named executive officer of Immunovant; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2019

$2,878,003

Salary $283,194Stock awards $0Bonus $85,000

2nd of 3 named executive officers at Immunovant by FY2019 total.

4 named officers on file for Immunovant, FY2019

Robert FAAAAI’s pay file — $29

  • 1 fiscal year of pay, line by line
  • IMVT’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Immunovant’s whole pay program stands against its peers

  • Immunovant’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on IMVT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed July 9, 2020 (DEF 14A).

Free

Get Robert FAAAAI’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Robert FAAAAI compensation by year

Immunovant Summary Compensation Table · the one fiscal year held
In US dollars, as Immunovant reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019
Salary$283,194
Bonus$85,000
Stock awards$0
Option awards$2,509,809
Non-equity incentive$0
Pension and deferred compensation$0
All other$0
Total$2,878,003

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Immunovant, Inc. DEF 14A filed July 9, 2020, accession 0001193125-20-190442, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Immunovant, Inc. filed document, accession 0001193125-20-190442. Every figure is read from that document and cited to the page and table it appears in. Filed July 9, 2020.

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
Option380,325—$7.86

Per the Outstanding Equity Awards at Fiscal Year-End table in Immunovant, Inc.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.

Immunovant’s named executive officers, FY2019

as the company reported each
Named executive officerRoleFY2019 total
Peter SalzmannChief Executive Officer$8,806,834
Robert FAAAAI · this pageFormer Chief Medical Officer$2,878,003
Pamela ConnealyChief Financial Officer (10)$2,775,934
Roderick WongFormer Chief Executive Officer of HSAC—

The full Immunovant compensation record

free company brief

This page is one person within Immunovant's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Immunovant proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Immunovant's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Robert FAAAAI's compensation dossier · One-time report. No refunds.